Dossier · Research-Context Dosage
What Was Actually Studied
An editorial reading of the doses, routes, durations, and pharmacokinetics documented in the BPC-157 preclinical literature — and the three small human pilot datasets that extend the record into human administration.
Research doses — not prescriptions
Everything on this page is a record of what was administered in published animal studies or small human pilot reports — not a recommendation. In rodent research, BPC-157 is most commonly studied at 10 micrograms per kilogram by intraperitoneal injection, though the same effects have been observed at doses a thousand times smaller (10 nanograms per kilogram). The only published human doses are 10–20 mg given by intravenous infusion in a two-person safety pilot, and unspecified amounts injected into knee joints or instilled into the bladder in small case series. The half-life — how quickly the peptide is cleared — is under 30 minutes in rats and dogs. No approved human dosing protocol exists, and the FDA classifies BPC-157 as an unapproved new drug.
Research Context Only
BPC-157 is not approved for human use by the FDA or any other major regulatory agency as of 2025. Every dose figure on this page describes what was studied in preclinical animal models or reported in small human pilot studies — not what is recommended, prescribed, or appropriate for human administration. The framing throughout is 'studied at X µg/kg in species Y via route Z.' Nothing here constitutes medical advice, clinical guidance, or a prescription.
With that framing established, the preclinical dosage literature for BPC-157 is unusually wide in its range. The compound has been studied at doses spanning twelve orders of magnitude — from 10 picograms per kilogram to 20 milligrams per kilogram — across six routes of administration in rodents, dogs, and three small human cohorts. Understanding what was studied, and how the outcomes varied across that range, is the purpose of this page.
Preclinical Dose Range and Routes Studied
The most commonly used preclinical dose in rodent models is 10 micrograms per kilogram (10 µg/kg) by intraperitoneal injection. This dose appears across gastric protection, liver protection, tendon healing, anastomosis healing, NSAID counteraction, and ischemia-reperfusion protection studies. At this dose, researchers have consistently documented protective effects without adverse findings [1][8][9][10][12].
A lower dose of 10 nanograms per kilogram (10 ng/kg) — one thousandth of the 10 µg/kg dose — has been studied extensively and found equipotent to the higher dose in multiple models. Achilles tendon-to-bone healing, intestinal anastomosis promotion, liver protection, and NSAID-toxicity counteraction have all been documented at 10 ng/kg as well as at 10 µg/kg [11][18]. This dose-equivalence across a thousandfold range is a feature of the published literature that authors have noted as unusual but consistent.
An ultra-low dose of 10 picograms per kilogram (10 pg/kg) was studied in the Achilles detachment model, producing measurable improvements in Achilles Functional Index and biomechanical parameters [11].
For oral administration, the primary research model uses drinking water supplemented to a concentration of 0.16 micrograms per milliliter (for the µg/kg equivalent) or 0.16 nanograms per milliliter (for the ng/kg equivalent), delivering approximately 12 mL per rat per day. Oral-route effects have been documented for gastrointestinal protection, liver protection, NSAID counteraction, and anastomosis healing — consistent with the peptide's unusual gastric-acid stability [1][12][18].
Topical cream at 1 microgram per gram of cream was studied in wound healing models in rats and small-type pigs, without adverse effects at any application [12].
For single-dose intramuscular tolerance, 20 mg/kg in rats produced no adverse effects [2]. In beagle dogs, 10 mg/kg by intramuscular route over 28 days was the primary repeated-dose safety dose [2]. These represent the upper range of doses studied for safety characterization — well beyond any therapeutic range studied in efficacy models.
Intraperitoneal, oral gavage, drinking water, intramuscular, intravenous, subcutaneous, topical cream, intravesicular, intra-articular, and local bath application have all been used as research administration routes across the literature. The breadth of routes studied reflects both the compound's physicochemical stability and the diversity of research groups exploring it across different tissue targets [1][12][13].
Pharmacokinetics: Half-Life, Bioavailability, and Clearance
The most comprehensive published pharmacokinetic dataset for BPC-157 is He et al. (2022) in Frontiers in Pharmacology, which characterized absorption, distribution, metabolism, and excretion across three escalating intramuscular doses in both Sprague-Dawley rats and beagle dogs, plus a single intravenous dose in each species [13].
The elimination half-life was under 30 minutes in both species following intramuscular administration [13]. In rats, the time to maximum plasma concentration (Tmax) after intramuscular dosing was approximately 3 minutes. In beagle dogs, Tmax was 6 to 9 minutes post-intramuscular injection. Intramuscular bioavailability was 14 to 19% in rats and 45 to 51% in dogs — a notably higher bioavailability in the dog, consistent with the dog's larger muscle mass and blood supply at the injection site [13].
Pharmacokinetics were linear across all doses studied — no saturation kinetics, no dose-dependent accumulation [13]. Primary tissue distribution was to kidney, liver, stomach, spleen, and thymus. Brain accumulation was minimal [13]. Excretion occurred via urine and bile.
Metabolism: BPC-157 breaks down primarily into proline and the other constituent amino acids of its 15-amino-acid sequence, which re-enter normal amino acid metabolic pathways [13]. This pathway produces no documented toxic metabolites and is mechanistically consistent with the compound's endogenous origin from human gastric juice protein.
In the human IV infusion pilot, plasma concentrations returned to baseline within 24 hours of the 20 mg infusion — the highest dose administered to humans in any published study [6]. No accumulation was observed between day one (10 mg) and day two (20 mg).
The pharmacokinetic profile — short half-life, linear kinetics, amino acid metabolism, rapid plasma clearance — is one of the mechanistic arguments made in the safety literature for the compound's preclinical tolerance at very high doses [1][2][13]. It does not establish safety in the clinical sense, which requires completed controlled trials, but it is part of the published mechanistic discussion.
Human Pilot Dosing: What Was Administered
The three published human pilot datasets represent three different routes and dose presentations.
The Lee and Burgess (2025) intravenous infusion study administered 10 mg BPC-157 by one-hour IV infusion on day one and 20 mg on day two, in two healthy adult volunteers [6]. This is the highest absolute dose administered to humans in any published study. No adverse events were documented at either dose, and comprehensive laboratory monitoring showed no clinically meaningful changes.
The Lee and Padgett (2021) intra-articular knee study administered BPC-157 by direct intra-articular injection in 17 patients with chronic knee pain [14]. The specific dose per injection is not reported in the published abstract; the study was conducted under a clinic protocol. No adverse events were documented.
The intravesicular instillation study for interstitial cystitis administered BPC-157 directly into the bladder via catheter [21]. Dose details are protocol-specific. No adverse effects were reported.
These are pilot datasets. They establish that BPC-157 has been administered to humans by intravenous, intra-articular, and intravesicular routes without documented adverse events in any published report. They do not constitute clinical-grade safety data and they do not support extrapolation to broader human use. The absence of completed randomized controlled trials is the critical gap in the human evidence base.